Switch theme
Sign up to access all valuation multiples
Farmacosmo SpA is a wellness e-commerce company active in the Health, Pharma, and Wellness industry, authorized by the Italian Ministry of Health to sell pharmaceutical products online. In particular, the company offers parapharmaceutical products, vitamins and food supplements, dietetic products, medical devices, cosmetic products, personal hygiene products, hair care products, dental care products, skincare products, perfumes, home and baby items.
2013
n/a
LTM Revenue n/a
LTM EBITDA n/a
$31.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Farmacosmo has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Farmacosmo achieved revenue of $76.9M and an EBITDA of -$0.4M.
Farmacosmo expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Farmacosmo valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $70.7M | $76.9M | XXX | XXX | XXX |
| Gross Profit | n/a | $11.0M | XXX | XXX | XXX |
| Gross Margin | NaN% | 14% | XXX | XXX | XXX |
| EBITDA | -$0.1M | -$0.4M | XXX | XXX | XXX |
| EBITDA Margin | 0% | -1% | XXX | XXX | XXX |
| Net Profit | n/a | -$2.2M | XXX | XXX | XXX |
| Net Margin | NaN% | -3% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Farmacosmo's stock price is EUR 1 (or $1).
Farmacosmo has current market cap of EUR 27.1M (or $29.1M), and EV of EUR 29.0M (or $31.2M).
See Farmacosmo trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $31.2M | $29.1M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Farmacosmo has market cap of $29.1M and EV of $31.2M.
Farmacosmo's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Farmacosmo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Farmacosmo and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $31.2M | XXX | XXX | XXX |
| EV/Revenue | 0.4x | XXX | XXX | XXX |
| EV/EBITDA | -71.5x | XXX | XXX | XXX |
| P/E | -8.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpFarmacosmo's NTM/LTM revenue growth is n/a
Farmacosmo's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Farmacosmo's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Farmacosmo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Farmacosmo and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 459% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 26% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Oriola | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Farmacosmo acquired XXX companies to date.
Last acquisition by Farmacosmo was XXXXXXXX, XXXXX XXXXX XXXXXX . Farmacosmo acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Farmacosmo founded? | Farmacosmo was founded in 2013. |
| Where is Farmacosmo headquartered? | Farmacosmo is headquartered in Italy. |
| Is Farmacosmo publicy listed? | Yes, Farmacosmo is a public company listed on MIL. |
| What is the stock symbol of Farmacosmo? | Farmacosmo trades under COSMO ticker. |
| When did Farmacosmo go public? | Farmacosmo went public in 2022. |
| Who are competitors of Farmacosmo? | Similar companies to Farmacosmo include e.g. MedPlus India, Pague Menos, Droga Raia, Redcare Pharmacy. |
| What is the current market cap of Farmacosmo? | Farmacosmo's current market cap is $29.1M |
| What is the current revenue growth of Farmacosmo? | Farmacosmo revenue growth between 2023 and 2024 was 9%. |
| Is Farmacosmo profitable? | Yes, Farmacosmo is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
